CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 42 enrolled
Drug / intervention
filgrastim +6 morebiological
Likely dose
filgrastim 480 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00265889
NCT00265889Phase 2Completed

Tandem Autologous Stem Cell Transplantation for Patients With Primary Progressive or Poor Risk Recurrent Hodgkin's Disease

Case Comprehensive Cancer Center·interventional·Posted Dec 15, 2005·Updated Nov 20, 2013

In Brief

A Phase 2 clinical trial evaluating filgrastim, busulfan, and 5 other interventions for Lymphoma. Completed, enrolled 42 participants across 1 site.

Detailed Summary

RATIONALE: Giving two autologous stem cell transplants (one after the other) may be an effective treatment for Hodgkin's lymphoma. PURPOSE: This phase II trial is studying how well giving two autologous stem cell transplants works in treating patients with progressive or recurrent Hodgkin's lymphoma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLymphoma
CountriesUnited States

Timeline

Phase 2CompletedFinished
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 15, 2005
Enrollment StartFeb 1, 2002
Primary CompletionApr 1, 2010
TodayJul 2, 2026
Enrollment to primary: 8.2 yearsPosted 20.5 years ago

Interventions

filgrastimbiological

480 mcg beginning day +5

busulfandrug

11.2 mg/kg; 0.8 mg/kg IV q6h X 14 doses

cyclophosphamidedrug

60 mg/kg IV over 2 hours x 2 days

etoposidedrug

60 mg/kg, IV

melphalandrug

150mg/m2 in NS at a concentration of 0.4mg/cc infused over 60 minutes.

autologous-autologous tandem hematopoietic stem cell transplantationprocedure

autologous-autologous tandem hematopoietic stem cell transplantation

radiation therapyradiation

radiation therapy